5/15/2026

GFL-Secure Deal Gets Proxy Firms’ Backing Despite Abrams’ Opposition

Bloomberg (05/15/26) Sambo, Paula

Two major proxy advisory firms backed GFL Environmental Inc.’s (NYSE: GFL) proposed acquisition of Secure Waste Infrastructure Corp. (SES.TO), dealing a setback to Abrams Capital Management, the investor fighting the deal. Institutional Shareholder Services (ISS) and Glass Lewis recommended that Secure Waste investors vote for the transaction. GFL offered C$24.75 per share in cash and stock for the Calgary-based waste management firm last month, valuing it at around C$6.4 billion ($4.6 billion) including debt. Abrams, which says it owns about 10% of Secure, argues the company has more long-term potential as a standalone business and has been urging shareholders to reject it ahead of a May 27 special meeting. ISS said there was “insufficient evidence to conclude the valuation is not credible,” despite the absence of a formal auction process. Similarly, Glass Lewis wrote that the price appears to be close to Secure's “fully marketed control value” under current market conditions. Under the agreement, Secure shareholders can elect to receive C$24.75 a share in cash, 0.4195 of a GFL subordinate voting share, or a mix of cash and stock. Secure shareholders are expected to own about 16% of the combined company if the transaction proceeds. The deal needs majority approval of shares voted, excluding insiders. “We are pleased that ISS and Glass Lewis have recommended Secure shareholders vote for the proposed transaction with GFL,” Secure Chair Mick Dilger said in a statement Friday. The recommendations reinforced the board’s view that the merger delivers “compelling immediate value” while allowing shareholders to own a piece of a larger and more diversified company, he said.

Read the article

5/15/2026

Mercy Investment Services, SOC Investment Group, and Trillium Asset Management Push to Oust Former Target CEO From Board

Retail Dive (05/15/26) James, Dani

A group of investors is urging Target shareholders to vote against the reelection of Executive Chair Brian Cornell and Lead Independent Director Christine Leahy at the retailer’s annual shareholder meeting in June. Among the reasons cited is Leahy’s oversight of the decision to retain former CEO Cornell as executive chair and special adviser, per a letter to shareholders filed in a notice of exempt solicitation on Friday. “In our view, Target has endured years of strategic and operational missteps that have led to significant underperformance compromising long-term shareholder value,” the letter from Mercy Investment Services, SOC Investment Group and Trillium Asset Management states. “The recent CEO succession does not signal that the Board is focused on the genuine reset we believe is critical to turn the Company around.” While Target did not directly comment on the investor letter, the retailer directed Retail Dive to its 2026 proxy statement, which outlines the directors nominated and their respective qualifications. Cornell’s departure as CEO was first announced in August, with company veteran Michael Fiddelke named as his successor. When the move was announced, some industry experts questioned how Fiddelke would be able to make the necessary changes needed at the struggling company while his former boss, Cornell, would remain in the boardroom. Fiddelke formally took over the chief executive role in February and has since unveiled some of the core components of his turnaround strategy. The approach centers on an effort to regain merchandising authority, which includes revamps of the beauty and baby sections in stores, as well as refreshes of some Target private label brands. “Given the persistent performance weaknesses at Target, we were surprised at the Board's decision to promote former COO Fiddelke, rather than hire an outsider,” the investors said in their letter. “While we are prepared to give Mr. Fiddelke a chance to turn Company performance around, the potential pitfalls of this decision are compounded by former CEO Cornell's continued presence on the Board in the powerful Executive Chair role and as Special Advisor to management. Although the arrangement is currently slated to be short-lived, lasting until March 2027, we believe that Target is at a critical juncture and cannot afford another year of the status quo.” Target’s Q4 net sales decreased 1.5% year over year to $30.5 billion, with comparable store sales down 3.9%, per a March release. The retailer expects net sales to increase about 2% for fiscal year 2026, with a “small increase” in comps and growth in net sales for each quarter.

Read the article

5/14/2026

Dexcom to Appoint Two Directors, Revamp Board Committee With Elliott

Reuters (05/14/26) Mahatole, Siddhi

Medical device maker Dexcom (DXCM.O) said on Thursday it will appoint two independent directors and revamp a key board committee in collaboration with Elliott Investment Management. Shares of Dexcom were up about 6% in after-hours trading. Dexcom CEO Jake Leach said on an investor call that the company is focusing on refreshing its board and seeks to add independent directors with medtech and operations expertise, an area where it currently lacks representation, as it positions for future growth. The company said the new appointments, to be announced at a later date, would bring the total number of independent directors appointed since early 2023 to six. Dexcom also said its Technology Committee will be renamed the Operations and Innovation Committee, with an expanded mandate to oversee operations, quality and the company's technical roadmap. "We also see a clear path to significant margin expansion, underpinning one of the most compelling earnings growth profiles in MedTech," said Marc Steinberg, partner at Elliott, in a statement. The Centers for Medicare & Medicaid Services is expected to decide on expanding Medicare coverage for continuous glucose monitors, which could offer a boost for device makers such as Dexcom. Leach said Dexcom does not expect the change in 2026 and sees it more likely in 2027, adding that it is prepared for an earlier rollout, which he said would be an "upside." Last month, the company beat Wall Street estimates for quarterly profit and revenue, however, it maintained its expectations for annual revenue in the range of $5.16 billion to $5.25 billion.

Read the article

5/14/2026

Pacira BioSciences Stock (US6951271005): DOMA Perpetual Capital Management Nominates Three Board Directors

Ad Hoc News (05/14/26)

Pacira BioSciences (NASDAQ: PCRX) faces a proxy contest as DOMA Perpetual Capital Management (DOMA) has nominated three independent board candidates, according to a definitive proxy statement filed on May 13, 2026. DOMA, which beneficially owns approximately 7.5% of Pacira's outstanding shares, is urging shareholders to vote for its slate of highly qualified independent directors at the upcoming annual meeting. The nomination comes amid scrutiny of Pacira's financial performance. According to Investing.com as of May 13, 2026, Pacira's total revenues increased just 4% in 2025, while research and development spending rose 44% and selling, general and administrative expenses increased 25%. This divergence between modest revenue growth and accelerating costs has drawn investor attention to the company's capital allocation strategy. DOMA Perpetual's nomination of three board directors reflects broader concerns about operational efficiency and strategic direction. According to PR Newswire as of May 13, 2026, DOMA issued a letter to shareholders urging them to vote for its slate on the white proxy card. The investor's position reflects a view that current board composition may not be adequately addressing cost structure and capital efficiency issues, particularly given the 25% increase in SG&A expenses in 2025 alongside modest revenue growth.

Read the article

5/13/2026

EagleBank Hires Western Alliance Exec as Its Next CEO

Banking Dive (05/13/26) Ennis, Dan

Eagle Bancorp (NASDAQ: EGBN) has hired Western Alliance (NYSE: WAL) executive Stephen Curley as its next CEO, the Bethesda, Maryland-based lender announced Tuesday. Curley, Western Alliance’s chief banking officer for national lines, will join EagleBank on July 6 and serve on the bank’s board, the lender said. The hire ends $9.9 billion-asset Eagle’s six-month search for a successor to CEO Susan Riel, who announced in November she would retire. The search drew fire from investor Diligence Capital Management, which outlined four proposals for the future of Eagle’s business, and demanded the ouster of three board members. In turn, Diligence suggested three replacement board candidates – selected for their experience reducing risk tied to an overreliance on commercial real estate. “[We’ll] still be a strong player in commercial real estate, but … we’re going to add some other specialties. We’re going to balance and diversify the balance sheet by doing more [commercial and industrial banking], we’ll do maybe a little more consumer, maybe a little bit of residential,” Curley told the executives. “I think it’s not real estate or something else. It’s both.” Curley said, however, that he does not want to “make hasty decisions,” and intends to evaluate the strengths and weaknesses of Eagle’s business lines in his first 90 days. At Western Alliance, Curley developed the bank’s specialized mortgage services business, which he continues to lead. He also helped shape the bank’s corporate finance, municipal lending and affordable housing efforts. Curley joined Western Alliance in 2009 and more recently began overseeing information technology, bank operations, branch banking, product development, and third-party risk management, according to his bio page with the Phoenix, Arizona-based bank. “My time at [Western Alliance] far surpassed what I could have imagined when I joined more than 16 years ago. I am deeply grateful for the trust, opportunities, and experiences the organization has given me,” Curley wrote Tuesday in a LinkedIn post. “I’m honored to have the opportunity to lead an organization with such a strong reputation for client relationships, community banking and disciplined growth.” Eagle, however, has been beset by what Riel last year called “asset quality challenges.” The bank last year saw two consecutive quarterly losses of roughly $70 million each but has since recovered to log $14.7 million in profit in the first quarter of 2026. Issues at the bank have proliferated for years, though. EagleBank agreed in 2022 to pay a $22.9 million penalty to the Securities and Exchange Commission and the Federal Reserve to settle claims the lender’s former CEO, Ron Paul – not to be confused with the former congressman – engaged in insider lending. The settlement marked the end of a three-year probe of EagleBank by the regulators into alleged third-party lending and improper disclosures. The bank disclosed the investigation to shareholders in 2019. Paul retired earlier that year, citing health concerns. He was permanently banned from working in the banking industry and fined $521,000. Riel, for her part, will remain CEO until July 5, Eagle said, and will stay on the bank’s board if she’s reelected Thursday at the company’s annual meeting. She’ll also continue as a consultant with the bank through July 27. “Susan’s tenure at EagleBank has been defined by steady and devoted leadership and maintaining a ‘Relationship First Culture’ that defines our values,” Eagle’s board chair, Jim Soltesz, said in a statement Tuesday. Curley also touched on culture in the video interview Eagle posted. He told Eagle executives he “felt so much alignment with the culture you have,” adding that any shift in culture would be “subtle.” “The key for us is being front and center with our customers, delivering exceptional advice, value and service,” Curley said. “Build a personal relationship and then underpin that with state-of-the-art technology. “With that, we can grow organically, we can grow through [mergers and acquisitions],” Curley added. Curley outlined his thoughts on how to address the needs of what he calls a “virtual circle” of individuals with interest in the bank. “What we all have to do is take care of the safety of the bank,” he said. “If we take care of the bank, the bank can take care of the employees. And if we take care of the employees, they’ll take care of the customers. … The customers, in turn, take care of the bank.”

Read the article

5/13/2026

UK Veterinary Group CVS Engaged by Converium Capital

Financial Times (05/13/26) Barnes, Oliver

One of the UK’s biggest veterinary care groups is facing pressure from Converium Capital to turn around its performance after competition regulators concluded a probe focused on high prices in the sector. Montreal-based fund Converium Capital has built a 2% stake in CVS Group (LON: CVSG) and threatened to rally shareholders to nominate directors to the board if the FTSE 250 group does not acquiesce to its demands, according to people familiar with the matter. In a letter to CVS’s board, seen by the FT, Converium called on CVS to launch a £100 million stock buyback “to capitalize on its currently languishing share price.” CVS’s market value stood at £785 million at Tuesday’s close, down more than 10% so far this year. The intervention comes after the UK’s Competition and Markets Authority in March unveiled a package of reforms imposed on five large pet care groups, including CVS, citing “weak competition and high prices” in the industry. The new rules — which include enhanced transparency standards and a cap on prescription charges on veterinary medicines — follow a years-long investigation into the companies, which together controlled 60% of the sector. Converium’s managing partner Michael Rapps, in the letter to CVS, expressed disappointment that the vet group’s share price had not improved following the conclusion of the CMA’s investigation and the company’s elevation to the FTSE 250 mid-cap index earlier this year. “The market is valuing CVS Group as if it were a single-location clinic rather than a multinational company with nearly 500 locations and a high-margin diagnostic lab business,” Converium said. It noted that the company, which also operates vet clinics in Australia, is valued far below private equity-backed rivals. Converium, which said it had previously engaged with management, said a £100 million buyback program would leave room for CVS to pursue up to £45 million worth of acquisitions and remain within its debt targets. “Repurchasing the company’s materially undervalued stock today is the highest-return use of capital available to the board,” said Converium. Converium, which was founded in 2020 by Aaron Stern formerly of Fir Trees Partners, previously engaged London-based estate agent Foxtons (LON: FOXT), unsuccessfully pushing for it to sell itself. It has also engaged a host of Japan’s biggest companies including Toshiba and Kirin Holdings (TSE: 2503).

Read the article